騰盛博藥-B逆市漲逾22% 高盛預計頭部企業將不斷提高運營效率

新浪港股

2025/02/20

熱點欄目自選股數據中心行情中心資金流向模擬交易

客戶端

　　騰盛博藥-B（02137）逆市上漲21.77%，現報1.51港元，成交額2764.64萬港元。

　　高盛認為，中國政府近年來推出的一系列創新激勵政策，正在為生物科技企業創造更加有利的發展環境。2024年《全鏈條支持創新藥發展實施方案》的出台，進一步優化了藥品審評審批、醫保支付、投孖展等政策環境，為創新藥企業提供了強有力的政策保障。高盛指出，中國作為創新來源地的地位日益凸顯，並將在全球範圍內獲得更廣泛的認可。該行持續看好中國的領先生物科技公司，預計數家頭部企業將在強勁的銷售增長和嚴格的支出控制下不斷提高運營效率，從而在2025/26年實現收支平衡。

海量資訊、精準解讀，盡在新浪財經APP

責任編輯：盧昱君

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2512461260"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2512461260\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2512461260?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-02-20 11:40","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2512461260","market":"hk","top_or_hot":-1,"title":"騰盛博藥-B逆市漲逾22% 高盛預計頭部企業將不斷提高運營效率","media":"新浪港股","content":"<html><body><div>\n<div>\n<div>\n<img src=\"http://image.sinajs.cn/n/hk/min/640x360xxfhd/02137.png\"/>\n</div>\n<div>\n<div>\n<span>熱點欄目</span>\n<s></s>\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n</div>\n客戶端\n</div>\n</div>\n<p>　　<span><a href=\"https://laohu8.com/S/02137\">騰盛博藥-B</a></span><span></span>（02137）逆市上漲21.77%，現報1.51港元，成交額2764.64萬港元。</p>\n<p>　　<a href=\"https://laohu8.com/S/GS\">高盛</a>認為，中國政府近年來推出的一系列創新激勵政策，正在為生物科技企業創造更加有利的發展環境。2024年《全鏈條支持創新藥發展實施方案》的出台，進一步優化了藥品審評審批、醫保支付、投孖展等政策環境，為創新藥企業提供了強有力的政策保障。高盛指出，中國作為創新來源地的地位日益凸顯，並將在全球範圍內獲得更廣泛的認可。該行持續看好中國的領先生物科技公司，預計數家頭部企業將在強勁的銷售增<span>長和</span><span></span>嚴格的支出控制下不斷提高運營效率，從而在2025/26年實現收支平衡。</p>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：盧昱君 </p>\n</div></body></html>","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>騰盛博藥-B逆市漲逾22% 高盛預計頭部企業將不斷提高運營效率</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n騰盛博藥-B逆市漲逾22% 高盛預計頭部企業將不斷提高運營效率\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">新浪港股</strong><span class=\"h-time small\">2025-02-20 11:40</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<div>\n<div>\n<img src=\"http://image.sinajs.cn/n/hk/min/640x360xxfhd/02137.png\"/>\n</div>\n<div>\n<div>\n<span>熱點欄目</span>\n<s></s>\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n</div>\n客戶端\n</div>\n</div>\n<p>　　<span><a href=\"https://laohu8.com/S/02137\">騰盛博藥-B</a></span><span></span>（02137）逆市上漲21.77%，現報1.51港元，成交額2764.64萬港元。</p>\n<p>　　<a href=\"https://laohu8.com/S/GS\">高盛</a>認為，中國政府近年來推出的一系列創新激勵政策，正在為生物科技企業創造更加有利的發展環境。2024年《全鏈條支持創新藥發展實施方案》的出台，進一步優化了藥品審評審批、醫保支付、投孖展等政策環境，為創新藥企業提供了強有力的政策保障。高盛指出，中國作為創新來源地的地位日益凸顯，並將在全球範圍內獲得更廣泛的認可。該行持續看好中國的領先生物科技公司，預計數家頭部企業將在強勁的銷售增<span>長和</span><span></span>嚴格的支出控制下不斷提高運營效率，從而在2025/26年實現收支平衡。</p>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：盧昱君 </p>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-20/doc-inemcarf3880265.shtml\">新浪港股</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2471134952.CNY","symbol_name":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-20/doc-inemcarf3880265.shtml","article_id":"2512461260","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2512461260","pubTimestamp":1740022800,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"　　騰盛博藥-B逆市上漲21.77%，現報1.51港元，成交額2764.64萬港元。　　高盛認為，中國政府近年來推出的一系列創新激勵政策，正在為生物科技企業創造更加有利的發展環境。高盛指出，中國作為創新來源地的地位日益凸顯，並將在全球範圍內獲得更廣泛的認可。該行持續看好中國的領先生物科技公司，預計數家頭部企業將在強勁的銷售增長和嚴格的支出控制下不斷提高運營效率，從而在2025/26年實現收支平衡。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4585":"ETF&股票定投概念","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","BK1587":"次新股","IE0004091025.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"B\" (USD) ACC","BK1574":"生物医药B类股","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","BK4127":"投资银行业与经纪业","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU0106831901.USD":"贝莱德世界金融基金A2","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4516":"特朗普概念","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","BK4504":"桥水持仓","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK4588":"碎股","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","BK4550":"红杉资本持仓","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","BK4552":"Archegos爆仓风波概念","02137":"腾盛博药-B","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","BK1161":"生物科技","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","IE0004086264.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"A\" (USD) ACC","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC"},"translate_title":"Tengsheng Boyao-B bucked the market trend and rose more than 22%. Goldman Sachs expects leading companies to continue to improve operational efficiency","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02137":1},"content_text":"熱點欄目\n\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n\n客户端\n\n\n　　騰盛博藥-B（02137）逆市上漲21.77%，現報1.51港元，成交額2764.64萬港元。\n　　高盛認為，中國政府近年來推出的一系列創新激勵政策，正在為生物科技企業創造更加有利的發展環境。2024年《全鏈條支持創新藥發展實施方案》的出台，進一步優化了藥品審評審批、醫保支付、投孖展等政策環境，為創新藥企業提供了強有力的政策保障。高盛指出，中國作為創新來源地的地位日益凸顯，並將在全球範圍內獲得更廣泛的認可。該行持續看好中國的領先生物科技公司，預計數家頭部企業將在強勁的銷售增長和嚴格的支出控制下不斷提高運營效率，從而在2025/26年實現收支平衡。\n\n\n\n海量資訊、精準解讀，盡在新浪財經APP\n\n責任編輯：盧昱君","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}